JP2013522292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522292A5 JP2013522292A5 JP2013500056A JP2013500056A JP2013522292A5 JP 2013522292 A5 JP2013522292 A5 JP 2013522292A5 JP 2013500056 A JP2013500056 A JP 2013500056A JP 2013500056 A JP2013500056 A JP 2013500056A JP 2013522292 A5 JP2013522292 A5 JP 2013522292A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- heterocyclyl
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 15
- -1 2 - piperazinyl Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000006682 monohaloalkyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004982 dihaloalkyl group Chemical group 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000033014 Plasma cell tumor Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000002797 childhood leukemia Diseases 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000009612 pediatric lymphoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 208000010626 plasma cell neoplasm Diseases 0.000 claims 1
- 201000008261 skin carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 0 *c1n[n]c2c1ccc(*c1ccccc1)c2 Chemical compound *c1n[n]c2c1ccc(*c1ccccc1)c2 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31440210P | 2010-03-16 | 2010-03-16 | |
| US61/314,402 | 2010-03-16 | ||
| PCT/US2011/025423 WO2011115725A2 (en) | 2010-03-16 | 2011-02-18 | Indazole compounds and their uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522292A JP2013522292A (ja) | 2013-06-13 |
| JP2013522292A5 true JP2013522292A5 (enExample) | 2014-04-03 |
Family
ID=43971357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013500056A Pending JP2013522292A (ja) | 2010-03-16 | 2011-02-18 | インダゾール化合物およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8987275B2 (enExample) |
| EP (1) | EP2547661A2 (enExample) |
| JP (1) | JP2013522292A (enExample) |
| KR (1) | KR20130006664A (enExample) |
| CN (1) | CN103080093A (enExample) |
| AU (1) | AU2011227643A1 (enExample) |
| BR (1) | BR112012023021A2 (enExample) |
| CA (1) | CA2791613A1 (enExample) |
| EA (1) | EA201290919A1 (enExample) |
| MX (1) | MX2012010617A (enExample) |
| WO (1) | WO2011115725A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| WO2012127030A1 (en) * | 2011-03-23 | 2012-09-27 | Proteosys Ag | Arylpiperazines as neuroprotective agents |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| JP6310470B2 (ja) * | 2012-11-01 | 2018-04-11 | ユニバーシティ オブ サウス カロライナ | 前立腺がんを処置するための方法 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016094846A1 (en) | 2014-12-11 | 2016-06-16 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis and related methods |
| EP3233840B1 (en) | 2014-12-16 | 2018-11-21 | Eudendron S.r.l. | Heterocyclic derivatives modulating activity of certain protein kinases |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| KR20170085619A (ko) | 2016-01-14 | 2017-07-25 | 연세대학교 산학협력단 | Alk 저해제에 대한 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 스타틴계 약물의 용도 |
| WO2018052773A1 (en) * | 2016-09-15 | 2018-03-22 | Boehringer Ingelheim International Gmbh | Pyridine and pyrazine compounds as inhibitors of ripk2 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| CN111138426B (zh) * | 2018-11-02 | 2023-03-10 | 安徽中科拓苒药物科学研究有限公司 | 吲唑类激酶抑制剂及其用途 |
| CN113164477A (zh) | 2018-12-14 | 2021-07-23 | 达纳-法伯癌症研究所股份有限公司 | C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途 |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11718612B2 (en) | 2019-09-06 | 2023-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12275721B2 (en) | 2019-10-03 | 2025-04-15 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2020391425A1 (en) | 2019-11-26 | 2022-06-16 | Board Of Regents, The University Of Texas System | Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4185568A1 (en) | 2020-07-24 | 2023-05-31 | The University of Rochester | Inhibitors of interleukin-1 receptor-associated kinases 1 and 4 |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| HU204253B (en) | 1982-11-22 | 1991-12-30 | Sandoz Ag | Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them |
| US4885314A (en) | 1987-06-29 | 1989-12-05 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
| US4782084A (en) | 1987-06-29 | 1988-11-01 | Merck & Co., Inc. | HMG-COA reductase inhibitors |
| US5420245A (en) | 1990-04-18 | 1995-05-30 | Board Of Regents, The University Of Texas | Tetrapeptide-based inhibitors of farnesyl transferase |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| EP0604181A1 (en) | 1992-12-21 | 1994-06-29 | Eli Lilly And Company | Antitumor compositions and method of treatment |
| WO1994019357A1 (en) | 1993-02-23 | 1994-09-01 | Merrell Dow Pharmaceuticals Inc. | Farnesyl:protein transferase inhibitors as anticancer agents |
| CA2118985A1 (en) | 1993-04-02 | 1994-10-03 | Dinesh V. Patel | Heterocyclic inhibitors of farnesyl protein transferase |
| US5843941A (en) | 1993-05-14 | 1998-12-01 | Genentech, Inc. | Ras farnesyl transferase inhibitors |
| US5602098A (en) | 1993-05-18 | 1997-02-11 | University Of Pittsburgh | Inhibition of farnesyltransferase |
| EP0670314A4 (en) | 1993-09-22 | 1996-04-10 | Kyowa Hakko Kogyo Kk | FARNESYL TRANSFERASE INHIBITORS. |
| US5721236A (en) | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| IL111235A (en) | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
| JP2875393B2 (ja) | 1993-10-15 | 1999-03-31 | シェーリング コーポレイション | Ｇ−タンパク質機能の阻害および増殖性疾患の治療に有用な三環式カルバメート化合物 |
| MY134819A (en) | 1993-10-15 | 2007-12-31 | Schering Corp | Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| US5719148A (en) | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| US5661152A (en) | 1993-10-15 | 1997-08-26 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| JPH09504295A (ja) | 1993-10-25 | 1997-04-28 | パーク・デイビス・アンド・カンパニー | タンパク質：ファルネシルトランスフェラーゼの置換されたテトラ‐およびペンタペプチド阻害剤 |
| US5783593A (en) | 1993-11-04 | 1998-07-21 | Abbott Laboratories | Inhibitors of squalene synthetase and protein farnesyltransferase |
| CA2152822A1 (en) | 1993-11-04 | 1995-05-11 | William R. Baker | Cyclobutane derivatives as inhibitors of squalene synthetase and protein farnesyltransferase |
| KR100362338B1 (ko) | 1993-11-05 | 2003-04-08 | 워너-램버트 캄파니 | 단백질:파르네실트랜스퍼라아제의치환디-및트리펩티드억제제 |
| US5484799A (en) | 1993-12-09 | 1996-01-16 | Abbott Laboratories | Antifungal dorrigocin derivatives |
| WO1995024612A1 (de) | 1994-03-07 | 1995-09-14 | International Business Machines Corporation | Verfahren und vorrichtung zur schnellen interpolation von zwischenwerten aus periodischen phasenverschobenen signalen und zur erkennung von defekten in einem drehkörper |
| CA2185441A1 (en) | 1994-03-15 | 1995-09-21 | Michael D. Lewis | Isoprenyl transferase inhibitors |
| US6312699B1 (en) | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
| HUT72440A (en) | 1994-03-31 | 1996-04-29 | Bristol Myers Squibb Co | Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them |
| US5523430A (en) | 1994-04-14 | 1996-06-04 | Bristol-Myers Squibb Company | Protein farnesyl transferase inhibitors |
| US5510510A (en) | 1994-05-10 | 1996-04-23 | Bristol-Meyers Squibb Company | Inhibitors of farnesyl protein transferase |
| US5563255A (en) | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| EP0764149B1 (fr) | 1994-06-10 | 1999-01-20 | Aventis Pharma S.A. | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5571792A (en) | 1994-06-30 | 1996-11-05 | Warner-Lambert Company | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
| WO1996005529A1 (en) | 1994-08-09 | 1996-02-22 | Micron Optics, Inc. | Temperature compensated fiber fabry-perot filters |
| DE69514367T2 (de) | 1994-08-11 | 2000-07-27 | Banyu Pharmaceutical Co., Ltd. | Substituierte amidderivate |
| CA2155448A1 (en) | 1994-08-11 | 1996-02-12 | Katerina Leftheris | Inhibitors of farnesyl protein transferase |
| EP0805154A1 (en) | 1994-08-12 | 1997-11-05 | Banyu Pharmaceutical Co., Ltd. | N,n-disubstituted amic acid derivative |
| DE4429506B4 (de) | 1994-08-19 | 2007-09-13 | Degussa Gmbh | Verfahren zur Extraktion natürlicher Carotinoid-Farbstoffe |
| DE4429653C2 (de) | 1994-08-20 | 1997-04-03 | Anton Dr More | Konverter und Verfahren zum Frischen von Metallschmelzen insbesondere von Roheisen zu Stahl |
| JP4319251B2 (ja) | 1994-11-22 | 2009-08-26 | エヌエックスピー ビー ヴィ | 半導体素子を有し導体トラックが形成されている基板が接着層により結合されている支持本体を有する半導体装置 |
| JPH10510261A (ja) | 1994-12-09 | 1998-10-06 | ワーナー−ランバート・カンパニー | タンパク質：ファルネシルトランスフェラーゼの置換テトラーおよびペンタペプチド阻害剤 |
| BR9606896A (pt) | 1995-01-09 | 1997-10-21 | Magla Int Ltd | Impressão de imagem resistente á água em superficies de látex |
| WO1996021456A1 (en) | 1995-01-12 | 1996-07-18 | University Of Pittsburgh | Inhibitors of prenyl transferases |
| FR2729390A1 (fr) | 1995-01-18 | 1996-07-19 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2730491B1 (fr) | 1995-02-09 | 1997-03-14 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2730492B1 (fr) | 1995-02-09 | 1997-03-14 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5684013A (en) | 1995-03-24 | 1997-11-04 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| US5700806A (en) | 1995-03-24 | 1997-12-23 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
| US5712280A (en) | 1995-04-07 | 1998-01-27 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US5891872A (en) | 1995-04-07 | 1999-04-06 | Schering Corporation | Tricyclic compounds |
| IL117798A (en) | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
| EP0820452B1 (en) | 1995-04-07 | 2003-06-04 | Schering Corporation | Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase |
| US5831115A (en) | 1995-04-21 | 1998-11-03 | Abbott Laboratories | Inhibitors of squalene synthase and protein farnesyltransferase |
| IL118101A0 (en) | 1995-05-03 | 1996-09-12 | Abbott Lab | Inhibitors of farnesyltransferase |
| WO1997000252A1 (en) | 1995-06-16 | 1997-01-03 | Warner-Lambert Company | Tricyclic inhibitors of protein farnesyltransferase |
| FR2736641B1 (fr) | 1995-07-10 | 1997-08-22 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
| AT402617B (de) | 1995-07-11 | 1997-07-25 | Datacon Schweitzer & Zeindl Gm | Anlage zum automatisierten, hermetischen anlage zum automatisierten, hermetischen verschliessen von gehäusen verschliessen von gehäusen |
| FR2736638B1 (fr) | 1995-07-12 | 1997-08-22 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
| CH690163A5 (fr) | 1995-07-28 | 2000-05-31 | Symphar Sa | Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers. |
| ATE236632T1 (de) | 1995-11-06 | 2003-04-15 | Univ Pittsburgh | Inhibitoren der protein-isoprenyl-transferase |
| CA2238081A1 (en) | 1995-11-22 | 1997-05-29 | S. Jane Desolms | Inhibitors of farnesyl-protein transferase |
| DE69635966T2 (de) | 1995-12-08 | 2006-11-30 | Janssen Pharmaceutica N.V. | (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren |
| SK86198A3 (en) | 1995-12-22 | 1999-02-11 | Schering Corp | Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases |
| AU1529997A (en) | 1996-01-16 | 1997-08-11 | Warner-Lambert Company | Substituted histidine inhibitors of protein farnesyltransferase |
| US6673927B2 (en) | 1996-02-16 | 2004-01-06 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Farnesyl transferase inhibitors |
| EP0944388A4 (en) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| WO1997044350A1 (en) | 1996-05-22 | 1997-11-27 | Warner-Lambert Company | Inhibitors of protein farnesyl transferase |
| CA2260216A1 (en) | 1996-07-15 | 1998-01-22 | Bristol-Myers Squibb Company | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase |
| AU6013998A (en) | 1996-12-30 | 1998-07-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2276150A1 (en) | 1996-12-30 | 1998-07-09 | Steven D. Young | Inhibitors of farnesyl-protein transferase |
| JP2002536968A (ja) | 1999-01-29 | 2002-11-05 | イムクローン システムズ インコーポレイティド | Ｋｄｒに特異的な抗体およびその使用 |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| EP1187633A4 (en) | 1999-04-08 | 2005-05-11 | Arch Dev Corp | USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| AU2002353186A1 (en) * | 2001-12-19 | 2003-06-30 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
| FR2836915B1 (fr) * | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| WO2003097610A1 (en) | 2002-05-17 | 2003-11-27 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| GB0217757D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| KR100976076B1 (ko) * | 2003-05-22 | 2010-08-17 | 아보트 러보러터리즈 | 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제 |
| US20040235892A1 (en) * | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
| SE0301906D0 (sv) | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
| FR2871158A1 (fr) * | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| DE102004028862A1 (de) * | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| US7632854B2 (en) * | 2004-11-17 | 2009-12-15 | Pfizer Italia S.R.L. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP1926734A1 (en) * | 2005-08-22 | 2008-06-04 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| WO2008074749A1 (en) * | 2006-12-20 | 2008-06-26 | Nerviano Medical Sciences S.R.L. | Indazole derivatives as kinase inhibitors for the treatment of cancer |
| WO2009028655A1 (ja) | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
| US20100197688A1 (en) * | 2008-05-29 | 2010-08-05 | Nantermet Philippe G | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
-
2011
- 2011-02-18 BR BR112012023021A patent/BR112012023021A2/pt not_active IP Right Cessation
- 2011-02-18 EP EP11713102A patent/EP2547661A2/en not_active Ceased
- 2011-02-18 CN CN2011800243883A patent/CN103080093A/zh active Pending
- 2011-02-18 US US13/583,974 patent/US8987275B2/en not_active Expired - Fee Related
- 2011-02-18 AU AU2011227643A patent/AU2011227643A1/en not_active Abandoned
- 2011-02-18 WO PCT/US2011/025423 patent/WO2011115725A2/en not_active Ceased
- 2011-02-18 KR KR1020127027019A patent/KR20130006664A/ko not_active Withdrawn
- 2011-02-18 EA EA201290919A patent/EA201290919A1/ru unknown
- 2011-02-18 CA CA2791613A patent/CA2791613A1/en not_active Abandoned
- 2011-02-18 JP JP2013500056A patent/JP2013522292A/ja active Pending
- 2011-02-18 MX MX2012010617A patent/MX2012010617A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008525530A5 (enExample) | ||
| JP2013544846A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2012153722A5 (enExample) | ||
| JP2019535746A5 (enExample) | ||
| JP2015517574A5 (enExample) | ||
| JP2019535744A5 (enExample) | ||
| JP2014520898A5 (enExample) | ||
| JP2010523670A5 (enExample) | ||
| JP2019514863A5 (enExample) | ||
| JP2016503799A5 (enExample) | ||
| JP2020515574A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2011511095A5 (enExample) | ||
| JP2013502441A5 (enExample) | ||
| JP2018510191A5 (enExample) | ||
| JP2013544860A5 (enExample) | ||
| JP2012504628A5 (enExample) | ||
| JP2010511721A5 (enExample) | ||
| JP2014508811A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| JP2016503414A5 (enExample) | ||
| RU2012151012A (ru) | Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием | |
| JP2017530171A5 (enExample) | ||
| JP2016513660A5 (enExample) |